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background:  Few studies have examined how antiplatelet therapies are selected during the routine care of acute MI patients, particularly 
relative to the patient’s predicted mortality and bleeding risks.
methods:  We examined STEMI/NSTEMI patients treated with PCI at 233 US hospitals in the TRANSLATE-ACS observational study 
from 4/2010 - 10/2012. Logistic regression models with forward variable selection were developed in an 80% sample, validated in a 20% 
sample, and refit on the entire study population. Prasugrel use rates were examined in relation to predicted mortality and bleeding using 
previously validated ACTION risk scores.
Results:  Among 11969 patients, 3123 (26%) received prasugrel at the time of PCI. The strongest predictors of prasugrel use included 
cardiogenic shock (OR 1.68), STEMI (OR 1.23), and male sex (OR 1.20). Transfer-in status (OR 0.50), prior anticoagulant use (OR 0.52), 
and prior stroke/TIA (OR 0.52) were associated with lowest likelihood of prasugrel use. As expected, prasugrel was used more often in 
patients at lower predicted bleeding risk, yet prasugrel use was also significantly lower in patients with higher predicted mortality (Figure). 
Prasugrel use was highest in patients at low mortality/low bleeding risk, but higher in patients at low mortality/high bleeding risk than those 
at high mortality/low bleeding risk.
conclusion:  In community practice, concern for bleeding may be a stronger driver of decision-making for antiplatelet therapy selection 
than mortality risk.
 
